The United States of America continuous glucose monitoring market size is estimated to be valued at USD 652.2 Million in 2025. It can reach a valuation of USD 1,177.0 Million by 2032, by exhibiting a CAGR of 8.8% throughout the forecast period (2025-2032).
The market growth is driven by the alarming levels of diabetes cases in the U.S. Technological advances that assist diabetics and non-diabetics in tracking their glucose levels can drive the sales of continuous glucose monitoring (CGM) devices.
However, the high costs of these devices and their limited coverage by insurance providers can hamper the market growth.
Key Market Insights
The United States of America continuous glucose monitoring market is likely to be shaped by government-sponsored healthcare programs and regulatory approvals of new devices.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/united-states-of-america-continuous-glucose-monitoring-market
United States of America Continuous Glucose Monitoring Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 652.2 Million |
|
Estimated Value by 2032 |
USD 1,177.0 Million |
|
Growth Rate |
8.8% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD million) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The United States of America continuous glucose monitoring market growth is driven by the awareness drives for non-CGM users. The use of live events and webinars to educate diabetics on selecting the right CGM device, combined with an understanding of data interpretation, can bode well for the market. Furthermore, the elimination of cost-containment requirements, broad formularies, and a wide range of CGM coverage criteria that align with the American Diabetes Association (ADA) can turn non-users into advocates or proponents of the technology.
The emergence of Latent Autoimmune Diabetes in Adults (LADA), also known as Type 1.5 Diabetes, is expected to compel CGM manufacturers to improve features in their offerings. The management of LADA with unpredictable glucose level fluctuations and the presentation of hypoglycemia at the onset of insulin therapy can drive the demand for better diagnostic tools. Additionally, the use of CGM devices for managing LADA can lead to a reduction in HbA1c levels and bode favorably for the market.
Market Opportunity: Application Beyond Insulin Users
The use of people interested in preventive health and real-time lifestyle tracking presents a viable opportunity for the United States of America continuous glucose monitoring market. The approval of over-the-counter (OTC) devices by Stelo or Lingo is an indicator of the high interest. This is illustrated by the availability of the Lingo Continuous Glucose Monitoring (CGM) system for purchase by Abbott Laboratories without the prior need of a prescription. The demand for consumer biowearables that provide personalized insights can pave the way for further innovation.
Market Challenge: Navigation of Insurance Coverage for Access to CGMs
Insurance coverage for access to CGM devices has been an exhaustive process for diabetics trying to gain access to it through Medicare schemes. The inability of most patients to pay out-of-pocket for their CGM devices led them to prefer traditional blood glucose monitoring methods. This challenge can be overcome through government intervention and the coverage of CGM devices in insurance schemes.
Analyst’s View
Recent Developments
DexCom, Inc. launched a photo logging feature for the G7, a continuous glucose monitoring system, on July 28, 2025. The feature allows patients to take photos of their meals, with the photo logging feature supported by AI that describes the ingredients in meals. This makes it easier to control glucose levels and eat portioned meals.
Competitor Insights
Market Segmentation
Related Reports :